merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safer option and more oversight compared to compounded drugs.</answer>
<question_number>2</question_number>
<answer>By offering vials through its own telehealth platform LillyDirect and direct delivery to patients, similar to telehealth companies.</answer>
<question_number>3</question_number>
<answer>Lack of FDA approval and less control over safety, quality, and effectiveness.</answer>
<question_number>4</question_number>
<answer>To regain market share from telehealth companies offering compounded drugs.</answer>
<question_number>5</question_number>
<answer>Allows compounding pharmacies to make copycat versions of drugs in shortage, including tirzepatide.</answer>
<question_number>6</question_number>
<answer>Direct sales through its own platform, transparent pricing, and removing third-party entities.</answer>
<question_number>7</question_number>
<answer>Vials may appeal to Medicare patients who currently lack coverage for weight-loss medications.</answer>
<question_number>8</question_number>
<answer>Implies vials are a safer, FDA-approved alternative to less regulated compounded drugs.</answer>
<question_number>9</question_number>
<answer>FDA "in shortage" list.</answer>
<question_number>10</question_number>
<answer>Lower pricing.</answer>